NCT06456528View on ClinicalTrials.gov

QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Cancer Treatment-Induced Thrombocytopenia
Interventions
DRUG

QL0911

QL0911

DRUG

QL0911 plus Placebo

QL0911 plus Placebo

DRUG

Placebo

Placebo

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06456528 - QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia | Biotech Hunter | Biotech Hunter